Polymarket Seeks $400M Funding Round, Targets $15B Valuation Amid Prediction Market Boom 
Huawei Expands Vietnam Presence Through Strategic Partnership with SHB Bank 
SpaceX Eyes $60B Cursor Deal to Boost AI Power Ahead of IPO 
SK Hynix to Invest $13 Billion in AI Chip Packaging Facility 
SK Hynix Launches 192GB SOCAMM2 Memory for Nvidia’s Next-Gen AI Chips 
OPmobility Reports Q1 Revenue Dip Amid Automotive Industry Slowdown 
Chinese Robotics Stocks React as Humanoid Robot Marathon Sparks Competition Concerns 
Eli Lilly in Talks to Acquire Kelonia Therapeutics for Over $2 Billion 
Elon Musk Faces French Probe Over X and Grok Amid Rising U.S.-EU Tensions 
J.P. Morgan Downgrades Essity AB on Rising Costs and Weak Earnings Outlook 
Nvidia Pushes 800V Data Center Power Systems to Boost Efficiency and Cut Costs 
JAPEX Shares Drop as Middle East Tensions Drive LNG Costs and Production Risks 
How Technology Is Reshaping Modern Business: From Operations to Customer Experience 
Indian Refiners Use Yuan via ICICI Bank to Pay for Iranian Oil Under U.S. Sanctions Waiver 
Florida Investigates OpenAI and ChatGPT Over Alleged Role in FSU Shooting 
LG Innotek Stock Hits Record High on $68M Automotive Wi-Fi 7 Deal 
Want to cut your energy bills? Here’s how five experts are doing it 
SAN DIEGO, March 06, 2017 -- TRACON Pharmaceuticals (NASDAQ:TCON), a clinical stage biopharmaceutical company focused on the development and commercialization of novel targeted therapeutics for cancer, wet age-related macular degeneration and fibrotic diseases, announced today that Charles Theuer, M.D, Ph.D., President and CEO, will present at the 29th Annual Roth Conference at 8:30 am PDT on Monday, March 13, 2017, at the Ritz Carlton in Dana Point, CA.
To access a live webcast of the presentation, please visit the “Events and Presentation” section within the “Investors” section of the TRACON Pharmaceuticals website at www.traconpharma.com. A replay of the webcast will be available on the website for 60 days following the event.
About TRACON
TRACON develops targeted therapies for cancer, ophthalmic and fibrotic diseases. The Company’s clinical-stage pipeline includes: TRC105, an endoglin antibody that is being developed for the treatment of multiple cancers; DE-122, the ophthalmic formulation of TRC105 that is being developed in wet AMD through a collaboration with Santen Pharmaceutical Company Ltd.; and TRC102, a small molecule that is being developed for the treatment of lung cancer and glioblastoma. To learn more about TRACON and its product candidates, visit TRACON's website at www.traconpharma.com.
Company Contact: Casey Logan Chief Business Officer (858) 550‐0780 ext. 236 [email protected] Investor Contact: Andrew McDonald LifeSci Advisors LLC 646-597-6987 [email protected]
